The technology for the fabrication of membranes with single nanopores has been developed at GSI over many years. Thin polymer films are irradiated with one individual high-energy heavy ion projectile (e.g. 1 GeV gold ion) at the linear accelerator UNILAC. As the ion passes through the film, it creates a nanoscopic damage trail that is converted into an open nanochannel by chemical etching. The precise diameter and the shape of the channel are adjusted by the etching parameters. For this work, asymmetric nanopores with a small opening of less than 50 nm were fabricated. The small size and the specific geometry ensure a particularly high level of sensitivity for transport processes through the channel.
GSI nanopore technology is the basis of other sensor options. Numerous groups around the world are developing specific functionalization strategies to impart selective functionalities to nanopore sensors. Nanopores in ion-track membranes are very versatile because they can be modified to respond to many different external changes, such as temperature, pH, light, voltage, or the presence of specific ion species, molecules, or drugs. GSI currently develops several highly sensitive sensor platforms and aims to integrate the functionalized nanopore membrane into a portable device for rapid and efficient virus detection and diagnosis.
Reference/s
Peinetti AS, Lake RJ, Cong W, Cooper L, Wu Y, Ma Y, Pawel GT, Toimil-Molares ME, Trautmann C, (2021): Direct detection of human adenovirus or SARS-CoV-2 with ability to inform infectivity using DNA aptamer-nanopore sensors. Contributed: Azzaroni O, Mariñas B, Rong L. Science Advances, September 22: 1-12.
Source: GSI Helmholtzzentrum für Schwerionenforschung GmbH / FAIR GmbH
Disclaimer: You agree that B2Bioworld is not responsible and will not be held liable for any third party content on its sites or any third-party content, products or services available on other web sites accessed through links from B2Bioworld sites. Links to third-party sites are for your convenience only, and their inclusion on B2Bioworld\'s sites does not imply any endorsement, guarantee, warranty or representation by B2Bioworld.
B2Bioworld offers you background information
On voice-assistants, clinical trials, pathologies, and the COVID-19 bet. Includes interview with Guy Fagherazzi, Luxembourg Institute of Health
Do’s and don’ts developing and selling viable tests for medical, agricultural, or food diagnostics in poor resource countries.
A systems look at DNA sequencing for personalized medicine by Leroy Hood, President Institute for Systems Biology, Seattle (US)
A view from quantum optics and interfaces between Physics, Information, and Biology.
A scientist’s strategy avoiding to get trapped by manufacturers of mass spectrometers with proprietary data formats
Marc Feiglin, at the time Chief Technology Officer Life Sciences at Tecan on electrowetting technology, blood diagnostic devices and prospects of clinical microfluidics